Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

A Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Research Question:
Does the drug MK-6482 work better than the drug everolimus in helping patients survive solid tumors?

Basic Study Information

Purpose:
The primary objective of this study is to compare MK-6482 to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that MK-6482 is superior to everolimus with respect to PFS and OS.

Location: University of Rochester Medical Center
Study Reference #: IGUK19181

Lead Researcher (Principal Investigator)

Lead Researcher:  Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: park_bogan@urmc.rochester.edu

Additional Study Details

Return to Search